Presented at #ERA24: FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function
The FDA reviewed this data before approving Ozempic, Wegovy, and Rybelsus, and UTIs are not listed in the prescribing information as a common or even uncommon adverse reaction
In AD, tau becomes abnormally phosphorylated, leading to its detachment from microtubules and aggregation into paired helical filaments that form NFTs
Semaglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management
Disclaimer: Weight loss results vary by individual and are influenced by adherence to the complete care plan, lifestyle modifications, and biological factors